Dexcom won FDA approval for its next-generation mobile communications device for diabetes monitoring, chalking up another regulatory win and furthering the company's R&D push.
Selecta Biosciences and the Juvenile Diabetes Research Foundation are widening their 2011 research collaboration for a Type 1 diabetes vaccine--and bringing in a little Big Pharma muscle, too.
The self-regulation of insulin delivery is a long-sought goal in the field, spurring the development of closed-loop systems and an artificial pancreas for diabetics. But some researchers are aiming smaller, looking at a way to create stem cells en masse that can produce insulin in response to blood sugar levels.
Researchers have identified a hormone that is associated with fructose, fibroblast growth factor 21 (FGF21), which increases rapidly in the blood after fructose ingestion. High FGF21 levels in the blood are associated with obesity, insulin resistance and nonalcoholic fatty liver disease in both humans and animals.
Scientists have discovered a blood biomarker useful in identifying patients at risk for developing diabetes.
Glooko has launched a small device that plugs into more than 30 existing blood glucose meters that can transmit data wirelessly to a smartphone, allowing health systems and payers to collect data on their diabetes patients with the monitors they already have.
Nightscout touts itself as an open source, do-it-yourself project to enable remote monitoring of blood glucose levels of patients with Type 1 diabetes.
With its candidate diabetes vaccine in Phase II combo studies, Diamyd Medical is seeing some new investment--including a bumped-up agreement with longtime partner Protein Sciences.
When it comes to engaging patients and teaching them to manage their Type 1 diabetes, Sanofi is starting young. The French drugmaker last week rolled out a new app aimed at children, designed to help them share their knowledge about the disease.
Endoscopic surgery isn't usually associated with diabetes, but Fractyl Laboratories yesterday announced encouraging clinical trial results for its endoscopic procedure to treat Type 2 diabetes and revealed a $40 million Series C financing round led by investment firm Mithril Capital Management.